More than 92 million Americans are currently taking a statin.1 And yet the dominant public conversation about LDL cholesterol (LDL-C) and cardiovascular risk remains stuck on a single, increasingly stale question: should I take one?
For patients with elevated LDL-C, the evidence supporting pharmacologic intervention is not meaningfully in dispute (despite what you might see online). The more interesting question—and the one that actually determines outcomes—is how to treat.
The modern lipid-lowering toolkit includes multiple drug classes that work by upregulating or modulating LDL receptors (LDLR)—the proteins on liver cells responsible for pulling potentially atherogenic lipoproteins out of circulation. Those drugs affect this process differently. Choosing among them requires understanding which pathway is driving a given patient’s LDL-C elevation and matching the intervention to that biology.
That’s what this piece is about: a decision-making framework for lipid-lowering pharmacotherapy. We’ll walk through what to measure at baseline, how to determine a person’s dominant cholesterol pathway, how to match first-line therapy to that pathway, and the growing role of PCSK9 inhibitors—a potent class of lipid-lowering agents. We’ll also cover when and how to escalate, and how to navigate the practical constraints—statin intolerance, insurance barriers, and monitoring—because no one should die of a disease we know how to prevent. And lipid lowering therapy is an important part of that process.
